Finland· FI-REL-REL3793
Indimacis 125
A 111in-indium antiovariumkarzinom-antikörper product containing igovomab, registered in Finland by CIS bio international.
Checked against Fimea (Finland) on
Informational only — not a medical device.
The record
At a glance
Fimea (Finland)- Active substance
- Igovomab
- Manufacturer
- CIS bio international
- Country
- Finland (FI)
- ATC code
- V09IB03
- ATC class
- 111In-Indium Antiovariumkarzinom-Antikörper
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under V09IB03
111in-indium antiovariumkarzinom-antikörper, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d20d0475-cfea-478d-a974-3103ac8e601a GET /v1/drugs/d20d0475-cfea-478d-a974-3103ac8e601a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "infuusioneste",
"route": null,
"ddd_unit": null,
"strength": "1 mg/ml",
"atc_label": "indium(111In)antiovariokarsinooma vasta-aine",
"ma_number": null,
"auth_status": "Myyntilupa peruuntunut",
"eu_ma_number": "EU/1/96/025/001",
"fimea_rel_id": "REL3793",
"authorised_at": "1996-10-04"
}See everything about 111in-indium antiovariumkarzinom-antikörper.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.